% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sperber:283101,
      author       = {Sperber, Pia Sophie and Hotter, Benjamin and Endres,
                      Matthias and Prüss, Harald and Meisel, Andreas},
      title        = {{A}nti-{NMDA}-{R}eceptor {G}lu{N}1 {A}ntibody {S}erostatus
                      {I}s {R}obust in {A}cute {S}evere {S}troke.},
      journal      = {Diagnostics},
      volume       = {15},
      number       = {24},
      issn         = {2075-4418},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DZNE-2025-01508},
      pages        = {3132},
      year         = {2025},
      abstract     = {Background: Anti-N-methyl-D-aspartate IgM and IgA
                      antibodies (NMDAR1-abs) are associated with unfavorable
                      stroke outcomes and may be risk factors thereof. However, to
                      utilize NMDAR1-abs serostatus for risk assessment in acute
                      stroke, it is crucial to understand the robustness of
                      serostatus during this phase. Therefore, we investigated the
                      robustness of NMDAR1-abs serostatus and titer levels up to
                      seven days after stroke. Methods: In this exploratory
                      analysis of the multicenter STRAWINSKI trial (identifier:
                      NCT01264549), patients with severe ischemic stroke (NIHSS
                      ≥ 9) in the middle cerebral artery territory were
                      included. The first blood sample was taken within 36 h and
                      then daily from day two to seven after stroke. NMDAR1-abs
                      immunoglobulin (Ig)A and IgM were assessed in serum using
                      cell-based assays. We initially measured NMDAR1-abs in the
                      total cohort on day 1. Subsequently, in samples from
                      seropositive and matched seronegative patients, we measured
                      NMDAR1-abs on each following day. Titer dilutions started
                      from 1:10 up to 1:1000. Seropositivity was defined as any
                      titer > 0. Results: Out of 171 patients (mean age = 76 [SD =
                      11], median NIHSS = 15 [IQR = 12-18]), 16 $(9\%)$
                      individuals were seropositive. Seropositive patients
                      remained seropositive and matched seronegative participants
                      remained seronegative over sequential measurements. Although
                      titer levels remained largely unchanged, some patients
                      showed fluctuating titers. Conclusions: The status of
                      NMDAR1-abs seropositivity is stable during acute stroke,
                      with little to no variation in titer levels.},
      keywords     = {NMDA-receptor (Other) / antibodies (Other) / biomarker
                      (Other) / stroke (Other)},
      cin          = {AG Prüß},
      ddc          = {610},
      cid          = {I:(DE-2719)1810003},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41464133},
      doi          = {10.3390/diagnostics15243132},
      url          = {https://pub.dzne.de/record/283101},
}